Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Rituximab and CHOP in PTLD
NCT01458548Phase 2Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Dec 2002
- Primary completion
- May 2008
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Orthosteric Ligands
- Countries
- 4
01
Overview
A Phase 2 trial of rituximab, cyclophosphamide, pegylated liposomal doxorubicin, vincristine sulfate liposome injection, prednisone in Post-Transplant Lymphoproliferative Disorder (PTLD), sponsored by Charité – Universitätsmedizin Berlin. Started Dec 2002; status: terminated.
02
Drugs
rituximabcyclophosphamidepegylated liposomal doxorubicinvincristine sulfate liposome injectionprednisone
03
Conditions
Post-Transplant Lymphoproliferative Disorder (PTLD)
Beyond the preview
Go deeper on NCT01458548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01458548.